Association between medicare and FDA policies and prior authorization requirements for buprenorphine products in Medicare part d plans

Mark, T. L., Parish, W., & Zarkin, G. A. (2019). Association between medicare and FDA policies and prior authorization requirements for buprenorphine products in Medicare part d plans. JAMA, 322(2), 166-167. https://doi.org/10.1001/jama.2019.6581

Abstract

This study describes changes in the proportion of Medicare Part D plans requiring prior authorization for buprenorphine products before and after a 2017 FDA rquirement that the drug’s label emphasize the importance of drug treatment of opioid use disorder.

Download/Explore

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Article

Use of a web-based portal to return normal individual research results in Early Check
Article

The importance of quality data to track global progress in addressing stillbirths and neonatal mortality
Article

Pre-natal exposure to NO2 and PM2.5 and newborn lung function